UroGen Pharma Ltd. 10-Q

Item 5. Other Information. None. 84 Table of Contents Item 6. Exhibits. The following exhibits are filed as part of this report: Exhibit Number Description 3.1 Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant ’ s Form 6-K (File No. 001-38079), filed with the SEC on May 18, 2017). 10.1 Second Amended and Restated Loan Agreement, dated as of February 26, 2026, by and among UroGen Pharma, Inc., as borrower and a Credit Party, the Registrant, as Parent and a Credit Party, the other guarantors signatory thereto or otherwise party thereto from time to time, as additional Credit Parties, BioPharma Credit PLC, as Collateral Agent, BPCR Limited Partnership, as a Lender, and BioPharma Credit Investments V (Master) LP as a Lender. 31.1 Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1# Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2# Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document – The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 The cover page from the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL # The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference. 85 Table of Contents Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. UroGen Pharma Ltd. May 6, 2026 By: /s/ Elizabeth Barrett Elizabeth Barrett Chief Executive Officer (Principal Executive Officer) May 6, 2026 By: /s/ Chris Degnan Chris Degnan Chief Financial Officer (Principal Financial and Accounting Officer) 86